Sravani Modumudi

Sravani Modumudi

Auto-generated profile, based on publicly available information

Sravani Modumudi

George Washington University School of Medicine and Health Sciences, Washington (DC), USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2026 in IJC Heart & Vasculature
Verified
Journal Article
Open access
LBLorenzo Bianchi
Lorenzo Bianchi
LALuisalice Afonso
Luisalice Afonso
TCTaras Chendey
Taras Chendey
SMSravani Modumudi
Sravani Modumudi
AMAndrea Minghini
Andrea Minghini
SHStephane Heymans
Stephane Heymans
Sodium-Glucose Cotransporter inhibitors (SGLTi) are established therapies for heart failure (HF), chronic kidney disease, and type 2 diabetes. Their role in hypertrophic cardiomyopathy (HCM) remains undefined. This systematic review synthesizes available evidence on SGLTi efficacy and safety in HCM. We systematically searched PubMed, Embase, and Cochrane to 2 June 2025 for studies reporting cardiovascular outcomes or safety adverse events in HCM patients treated with SGLTi. Three studies were included, comprising 5046 HCM patients, of whom 2523 (50%) received SGLTi. The population was predominantly male (68.9%), mean age 63.4 (±12.7), with high diabetes prevalence (90.6%). Cohorts were heterogeneous: one included 41.6% obstructive HCM, one only non-obstructive HCM, and one unspecified obstruction. Follow-up ranged 6–37.2 months. The high prevalence of diabetes and hypertension, along with limited genetic data, suggest some patients may have metabolic-mixed phenotypes rather than classic sarcomeric HCM. Two studies, (n = 4998, 90.5% diabetics) reported an association between SGLTi and reduced all-cause mortality. HF hospitalizations results were inconsistent: one study (n = 4126, 100% diabetics) showed reduction, while two other (respectively n = 48, 100% diabetics, and n = 872, 45.5% diabetics) resulted neutral. Two studies (n = 920) reported comparable adverse events. Evidence on SGLTi in HCM is limited, largely observational, and confined to diabetic-metabolic patients. Observed reduction in all-cause mortality likely reflects these metabolic or mixed phenotypes rather than classical sarcomeric HCM. Effects on HF hospitalizations remain uncertain. No safety concerns emerged. These findings are hypothesis-generating and highlight need for randomized controlled trials of SGLTi in HCM with or without diabetes.

5 February 2025 in The American Journal of Cardiology
Verified
Journal Article
Closed access
SMSravani Modumudi
Sravani Modumudi
CRChandana Padmanabham Reddy
Chandana Padmanabham Reddy